KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Deferred Taxes (2016 - 2025)

Eli Lilly (LLY) has disclosed Deferred Taxes for 17 consecutive years, with $748.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Deferred Taxes fell 22.61% year-over-year to $748.1 million, compared with a TTM value of $1.7 billion through Dec 2025, down 36.38%, and an annual FY2025 reading of $1.7 billion, down 36.38% over the prior year.
  • Deferred Taxes was $748.1 million for Q4 2025 at Eli Lilly, up from -$501.4 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $1.1 billion in Q3 2022 and bottomed at -$501.4 million in Q3 2025.
  • Average Deferred Taxes over 5 years is $485.9 million, with a median of $468.6 million recorded in 2023.
  • The sharpest move saw Deferred Taxes skyrocketed 4967.31% in 2023, then tumbled 216.66% in 2025.
  • Year by year, Deferred Taxes stood at $92.5 million in 2021, then crashed by 111.24% to -$10.4 million in 2022, then surged by 4967.31% to $506.2 million in 2023, then soared by 90.95% to $966.6 million in 2024, then dropped by 22.61% to $748.1 million in 2025.
  • Business Quant data shows Deferred Taxes for LLY at $748.1 million in Q4 2025, -$501.4 million in Q3 2025, and $1.1 billion in Q2 2025.